• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Predictive Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    9/29/25 9:47:54 AM ET
    $POAI
    Industrial Specialties
    Health Care
    Get the next $POAI alert in real time by email
    Form 8-K
    False000144615900014461592025-09-292025-09-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

    FORM 8-K

    _________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  September 29, 2025

    _______________________________

    Predictive Oncology Inc.

    (Exact name of registrant as specified in its charter)

    _______________________________

    Delaware001-3679033-1007393
    (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

    91 43rd Street, Suite 110

    Pittsburgh, Pennsylvania 15201

    (Address of Principal Executive Offices) (Zip Code)

    (412) 432-1500

    (Registrant's telephone number, including area code)

     

    (Former name or former address, if changed since last report)

    _______________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common stock, $0.01 par valuePOAINasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     
     
    Item 7.01. Regulation FD Disclosure.

    On September 29, 2025, Predictive Oncology Inc. (the “Company”) issued a press release announcing two private placements and its adoption of a digital asset treasury strategy. The Company intends to continue to pursue its current lines of business in addition to the pursuit of its digital asset treasury strategy.

    The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits 

    Exhibit No. Description of Exhibits
       
    99.1 Press Release dated September 29, 2025
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     Predictive Oncology Inc.
       
      
    Date: September 29, 2025By: /s/ Josh Blacher        
      Josh Blacher
      Interim Chief Financial Officer
      

     

    Get the next $POAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POAI

    DatePrice TargetRatingAnalyst
    8/19/2024$3.00Buy
    H.C. Wainwright
    6/30/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $POAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens

    Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements Predictive Oncology continues to execute on its artificial intelligence and machine learning business to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide   PITTSBURGH, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. ("Predictive Oncology" or the "Company") (NASDAQ: POAI) today announced the pricing of two private placement transactions to support its adoption of a digital asset treasury strategy under which the principal holding will be ATH, the native utility token of the Aet

    9/29/25 9:07:26 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Announces 1-for-15 Reverse Stock Split

    PITTSBURGH, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock. The reverse stock split will become effective at 12:01 a.m. on Tuesday, September 30, 2025. Predictive Oncology's common stock will continue to be traded on Nasdaq under the symbol POAI and will begin trading on a reverse split-adjusted basis when the market opens on Tuesday, September 30, 2025. The new CUSIP number for the Company's common stock following the reverse stock split will be 74039M408. The reverse stock split is pri

    9/25/25 8:00:03 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients

    PITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, today announced a strategic collaboration to identify and prioritize drugs for repurposing to improve patient outcomes and save lives. Predictive Oncology has a longstanding commitment to supporting the best treatments for patients diagnosed with cancer, through both proprietary clinical assays and AI-driven machine learning (ML). These capabilities allow for the rapid screening of a drug against a broad range of tumor types, with the goal of pred

    9/4/25 9:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    SEC Filings

    View All

    Predictive Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Predictive Oncology Inc. (0001446159) (Filer)

    9/29/25 6:32:50 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Predictive Oncology Inc. (0001446159) (Filer)

    9/29/25 9:47:54 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Predictive Oncology Inc. (0001446159) (Filer)

    9/25/25 8:05:53 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Predictive Oncology with a new price target

    H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

    8/19/24 6:55:24 AM ET
    $POAI
    Industrial Specialties
    Health Care

    HC Wainwright & Co. initiated coverage on Predictive Oncology with a new price target

    HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00

    6/30/21 6:22:58 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Litchfield Hills Research initiated coverage on Predictive Oncology with a new price target

    Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

    2/1/21 10:17:27 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chung-Welch Nancy was granted 64,680 shares, increasing direct ownership by 335% to 83,993 units (SEC Form 4)

    4 - Predictive Oncology Inc. (0001446159) (Issuer)

    9/11/25 5:46:18 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Director Handley Daniel E was granted 64,680 shares, increasing direct ownership by 380% to 81,698 units (SEC Form 4)

    4 - Predictive Oncology Inc. (0001446159) (Issuer)

    9/11/25 5:45:52 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Director Hawryluk Matthew was granted 64,680 shares, increasing direct ownership by 682% to 74,168 units (SEC Form 4)

    4 - Predictive Oncology Inc. (0001446159) (Issuer)

    9/11/25 5:45:24 PM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Leadership Updates

    Live Leadership Updates

    View All

    AIRNA Appoints Matthew Hawryluk as Chief Business Officer

    AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. "Matt is a tremendous addition to our leadership team, bringing extensive experience driving collaborations and leading high-performing teams," said Kris Elverum, President and CEO of AIRNA. "Matt joins us at a critical time, as we prepare to bring our first RNA editing therapeutic to the clinic. We have the pote

    1/30/25 7:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Renovaro Issues Shareholder Letter and Provides Corporate Update

    Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for

    1/7/25 9:15:00 AM ET
    $POAI
    $RENB
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

    EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. "Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleas

    6/27/23 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Financials

    Live finance-specific insights

    View All

    Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

    PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i

    11/13/24 7:00:21 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

    PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s

    8/14/24 7:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

    PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas

    8/7/24 7:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $POAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Predictive Oncology Inc. (Amendment)

    SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)

    2/11/22 7:50:59 AM ET
    $POAI
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed

    SC 13G - Predictive Oncology Inc. (0001446159) (Subject)

    3/1/21 6:23:16 AM ET
    $POAI
    Industrial Specialties
    Health Care